Calcium Pyruvate Exerts Beneficial Effects in an Experimental Model of Irritable Bowel Disease Induced by DCA in Rats

• Published in: Nutrients 2019-01, Vol.11 (1), p.140
• Main Authors: Rodríguez-Nogales, Alba, Algieri, Francesca, Vezza, Teresa, Garrido-Mesa, José, Molina-Tijeras, José Alberto, Rodríguez-Cabezas, María Elena, Utrilla, María Pilar, Pischel, Ivo, Gálvez, Julio
• Format: Article
• Language: English
• Subjects: Acids; Animal models; Animal tissues; Bioavailability; Biochemical analysis; Biomedical materials; Biomedical research; Bone resorption; Calcium; calcium pyruvate; Colitis; Colon; colorectal distension; deoxycholic acid; Evaluation; Filaments; Gene expression; Immune response; Inflammation; Inflammatory bowel disease; Interleukin 6; Interleukin 8; Intestine; irritable bowel disease; Irritable bowel syndrome; Laboratory animals; Lymphocytes; Lymphocytes B; Lymphocytes T; Mast cells; Mechanical stimuli; Metabolism; Metabolites; Osteopenia; Osteoporosis; Pain; Pain perception; Permeability; Post-menopause; Prevention; Probiotics; Pyruvic acid; referred pain; Rodents; Tumor necrosis factor-α; Vitamin D
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu11010140

Pyruvate is a normal constituent of the body that participates in carbohydrate metabolism and functions as a scavenger of free radicals. Calcium pyruvate monohydrate (CPM) is a more stable derivative that has proved its anti-inflammatory effect in experimental colitis, among other disorders, and that could also be considered a source of calcium. Thus, it would be useful for the treatment of diseases with an inflammatory component and a high prevalence of osteoporosis like the irritable bowel syndrome (IBS). The aim of the present study is to evaluate the effects of CPM in a rat model of chronic post-inflammatory visceral pain induced by deoxycholic acid (DCA) that resembles IBS. Rats were administered DCA for three days intracolonically and then treated daily with CPM (40 and 100 mg/kg) or gabapentin (70 mg/kg) (positive control) by oral gavage for 17 days. The treatments reduced the visceral hypersensitivity measured by response to colorectal distension and referred pain. DCA induced changes in the colonic immune response characterized by increased expression of the cytokine and the inducible enzyme , which was reduced by the treatments. DCA also decreased the gut expression of the mucins and , which was normalized by CPM, whereas gabapentin only increased significantly . Moreover, DCA increased the expression of , which was decreased to basal levels by all the treatments. However, the serotonin receptor , which was also elevated, was not affected by any of the treatments, indicating no effect through this signalling pathway. In conclusion, CPM ameliorated the visceral hypersensitivity and the referred pain caused by DCA, being as effective as the control drug. Furthermore, it improved the immune status of the animals, which could contribute to the visceral analgesia and the regeneration of the intestinal epithelial barrier integrity.